Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

American Journal of Psychiatry

Volumn 157, Issue 6, 2000, Pages 867-876

  Dieperink, Eric ^a,b   Willenbring, Mark ^a   Ho, Samuel B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C; HUMAN; MENTAL DISEASE; NEUROPSYCHIATRY; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; DEPRESSIVE DISORDER; EXERCISE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MENTAL DISORDERS; NARCOTIC ANTAGONISTS; PATIENT EDUCATION;

EID: 0034130730     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.6.867     Document Type: Review

References (103)

1. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26(3, suppl 1):2S-10S
2. Rall CJ, Dienstag JL: Epidemiology of hepatitis C virus infection. Semin Gastrointest Dis 1994; 6:3-12
3. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334:1685-1690
4. Coury-Cautilena C, Van Raden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, Di Bisceglie A, Hoofnagle J, Shih JW, Kaslow R, Ness P, Alter HJ: Routes of infection, viremia, and liver disease in asymptomatic individuals with hepatitis C virus infection. N Engl J Med 1996; 334:1691-1696
5. Marsano LS, Pena LR: The interaction of alcoholic liver disease and hepatitis C. Hepatogastroenterology 1998; 45:331-339
6. Corrao G, Carle F, Lepore AR, Zepponi E, Galatola G, Di Orio F: Interaction between alcohol consumption and positivity for antibodies to hepatitis C virus on the risk of liver cirrhosis: a case-controlled study. Eur J Epidemiol 1992; 8:634-639
7. Williams IT, Sabin K, Fleenor M, Judson F, Mottram K, Poujade J, Ryder P, Wise F, Alter MJ: Current patterns of hepatitis C virus transmission in the United States: the role of drugs and sex (abstract). Hepatology 1998; 28:497A
8. Detre KM, Belle SH, Lombardo M: Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996; 2:219-228
9. Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(3, suppl 1):34S-38S
10. Di Bisceglie AM: Hepatitis C. Lancet 1998; 351:351-355
11. Schiff ER: Hepatitis C and alcohol. Hepatology 1997; 26(3, suppl 1):39S-42S
12. Lee DH, Jamal H, Regenstein FG, Perrillo RP: Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997; 42:186-191
13. Johnson ME, Fisher DG, Fenaughty A, Theno SA: Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93:785-789
14. Radloff LS: The CES-D Scale: a self-report depression scale for research in the general population. J Applied Psychol Measurement 1977; 1:385-401
15. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L: Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37:93-97
16. Zung WWK: A self-rating depression scale. Arch Gen Psychiatry 1965; 12:63-70
17. Singh N, Gayowski T, Wagener MM, Marino IR: Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant 1997; 11:405-411
18. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
19. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer H Jr, Perrillo R, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321:1501-1510
20. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM: Effect of interferon-α treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42:2482-2486
21. Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K: Depression during interferon therapy in chronic hepatitis C patients - a prospective study. Seishin Shinkeigaku Zasshi 1997; 99:101-127
22. Pariante C, Orru M, Baita A, Farci M, Carpiniello B: Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354:131-132
23. Horiike N, Fujisawa T, Michitaka K, Tada K, Masumoto T, Iuchi H, Kojima N, Onji M: The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncol Rep 1998; 5:1171-1174
24. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A: Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83:901-909
25. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-789
26. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiftman M, Zeuzem S, Craxi A, Ling MH, Albrecht J: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:1493-1499
27. McHutchison JG, Gordon SC, Schiff ER, Schiffman ML, Lee W, Rustgi V, Goodman Z, Ling MH, Cort S, Albrecht J: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492
28. Davis G, Balart L, Schiff E, Lindsay K, Bodenheimer H, Perillo R, Carey W, Jacobson I, Payne J, Dienstag J, VanThiel D, Tamburro C, Martino F, Sangvhi B, Albrecht J: Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 1994; 16:334-343
29. Carithers RL Jr, Sugano D, Bayliss M: Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci 1996; 41(12 suppl):75S-80S
30. Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-212
31. Bonkovsky HL, Woolley JM (Consensus Interferon Study Group): Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29:264-270
32. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(3 suppl 1):112S-121S
33. Suter CC, Westmorland BF, Sharbrough FW, Hermann RC Jr: Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 1984; 59:847-850
34. Mattson K, Niiranen A, Iivanainen M, Farkkila M, Bergstrom L, Holsti L, Kamppinen H, Cantell K: Neurotoxicity of interferon. Cancer Treat Rep 1983; 67:958-961
35. Smedley H, Katrak M, Sikora K, Wheeler T: Neurological effects of recombinant human interferon. Br Med J 1983; 286: 262-264
36. Liberti AM, Biagini S, Perticoni G, Ricci S, D'Alessandro P, Senatore M, Cinieri S: Electrophysiological and neuropsychological functions in patients treated with interferon-β. J Interferon Res 1990; 10:613-619
37. Merimsky O, Chaitchik S: Neurotoxicity of interferon-α. Anticancer Drugs 1992; 3:567-570
38. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones B, Rustgi V, Jones A: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147:1577-1580
39. Derogatis LR: The SCL-90-R. Baltimore, Johns Hopkins University. Clinical Psychometrics Research Unit, 1975
40. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K: Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291
41. Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38-47
42. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
43. Maunder RG, Hunter JJ, Feinman SV: Interferon treatment of hepatitis C associated with symptoms of PTSD. Psychosomatics 1998; 39:461-464
44. Spitzer RL, Williams JBW, Gibbon M, First MB: Structured Clinical Interview for DSM-III-R - Non-Patient Edition (SCID-NP, Version 1.0). Washington, DC, American Psychiatric Press, 1990
45. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67:361-370
46. Smith A, Tyrrell D, Coyle K, Higgins P: Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology (Berl) 1988; 96:414-416
47. Meyers CA, Abbruzzese JL: Cognitive functioning in cancer patients: effects of previous treatment. Neurology 1992; 42: 434-436
48. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S: Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26: 596-600
49. Iivanainen M, Laaksonen R, Niemi M, Farkkila M, Bergstrom K, Mattson A, Niiranen A, Cantell K: Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985; 72: 475-480
50. Poutiainen E, Hokkanen L, Niemi M, Farkkila M: Reversible cognitive decline during high-dose α-interferon treatment. Pharmacol Biochem Behav 1994; 47:901-905
51. Adams F, Quesada J, Gutterman J: Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252:938-941
52. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR: Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996; 8:74-81
53. Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, Mascheroni L, Lenisa L, Cascinelli N: Neurotoxicity of interferon-α in melanoma therapy. Cancer 1998; 83:482-489
54. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M: Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45:947-950
55. Amato R, Meyers C, Ellerhorst J, Finn L, Kilbourn R, Sella A, Logothetis C: A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. Ann Oncol 1995; 6:911-914
56. Meyers C, Scheibel R, Forman A: Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41:672-676
57. Valentine A, Meyers C, Kling M, Richelson E, Hauser P: Mood and cognitive side effects of interferon-α therapy. Semin Oncol 1998; 25(suppl 1):39-47
58. Jones GJ, Itri LM: Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 1986; 57(8 suppl):1709-1715
59. Weiss K: Safety profile of interferon-α therapy. Semin Oncol 1998; 25(suppl 1):9-13
60. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K: Depression from interferon therapy in patients with hepatitis C (letter). Am J Psychiatry 1999; 156:1120
61. Janssen H, Brouwer J, van der Mast R, Schalm S: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21:241-243
62. Fukunishi K, Tanaka K, Takahashi M, Ueshima K, Maruyama K, Sakata I: Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998; 24:581-583
63. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
64. Capuron L, Ravaud A: Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state (letter). N Engl J Med 1999; 340:1370
65. Eysenck HJ, Eysenck SBG: Eysenck Personality Questionnaire Manual. San Diego, Calif, Educational and Industrial Testing Service, 1975
66. Quesada J, Talpaz M, Rios A, Kurzrock R, Gutterman J: Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4:234-243
67. Dean G, Spears L, Ferrell B, Quan W, Groshon S, Mitchell M: Fatigue in patients with cancer receiving interferon alpha. Cancer Pract 1995; 3:164-172
68. Piper B, Rieger P, Brophy L, Haeuber D, Hood LE, Lyver A, Sharp E: Recent advances in the management of biotherapy-related side effects: fatigue. Oncol Nurs Forum 1989; 16:27-34
69. Iancu I, Sverdlik A, Dannon P, Lepkifker E: Bipolar disorder associated with interferon-alpha treatment. Postgrad Med J 1997; 73:834-835
70. Strite D, Valentine A, Meyers C: Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997; 9:273-276
71. Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M: Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. J Neuropsychiatry Clin Neurosci 1997; 51:175-180
72. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC (Australian Hepatitis C Study Group): Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995; 23:487-496
73. Calvert MC, Gresser I: Interferon enhances the excitability of cultured neurons. Nature 1979; 178:558-560
74. Blalock JE, Smith EM: Human leukocyte interferon (HulFN-α): potent endorphin-like opioid activity. Proc Natl Acad Sci USA 1980; 77:5972-5974
75. Corsmitt EPM, Heijligenberg R, Endert E, Ackermans MT, Sauerwein HP, Romijn JA: Endocrine and metabolic effects of interferon-α in humans. J Clin Endocrinol Metab 1996; 81: 3265-3269
76. Barbarino A, Colasanti S, Corsello SA, Satta MA, Della Casa S, Rota CA, Tartaglione R, Barini A: Dexamethasone inhibition of interferon-α2-induced stimulation of cortisol and growth hormone secretion in chronic myeloproliferative syndrome. J Clin Endocrinol Metab 1995; 80:1329-1332
77. Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR: Adrenal gland enlargement in major depression: a computed tomographic study. Arch Gen Psychiatry 1992; 49: 384-387
78. Stokes PE, Sikes CR: The hypothalamic-pituitary-adrenocortical axis in major depression. Endocrinol Metab Clin North Am 1988; 17:1-19
79. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH: Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992: 102:2155-2160
80. Preziati D, La Rossa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P: Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132:587-593
81. Rothwell NJ, Hopkins SJ: Cytokines and the nervous system, II: actions and mechanisms of action. Trends Neurosci 1995; 18:130-136
82. Dentino A, Pieper C, Rao M, Currie M, Harris T, Blazer D, Cohen H: Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc 1999; 47:6-11
83. Miller A: Neuroendocrine and immune system interactions in stress and depression. Psychiatr Clin North Am 1998; 21: 443-463
84. Licinio J, King M, Hauser P: Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Semin Oncol 1998; 25(suppl 1):30-38
85. Ho BT, Huo YY, Lu JG, Tansey LW, Levin VA: Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha. Pharmacol Biochem Behav 1992; 42:57-60
86. Siever LJ, Davis KL: Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry 1985; 142:1017-1031
87. Lam RW, Levitan RD, Tam EM, Yatham LN, Lamoureux S, Zis AP: L-Tryptophan augmentation of light therapy in patients with seasonal affective disorder. Can J Psychiatry 1997; 42: 303-306
88. Ghadirian AM, Murphy BE, Gendron MJ: Efficacy of light versus tryptophan therapy in seasonal affective disorder. J Affect Disord 1998; 50:23-27
89. Delgado PL, Charney DS, Price LH, Aghajanian GK, Lundis H, Heninger GR: Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47:411-418
90. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C: Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Neuropsychopharmacology 1996; 15:465-474
91. Benkelfat C, Ellenbogen MA, Dean P, Palmour RM, Young SN: Mood-lowering effect of tryptophan depletion: enhanced susceptibility in young men at genetic risk for major affective disorders. Arch Gen Psychiatry 1994; 51:687-697
92. Hoffman BJ, Mezey E, Brownstein MJ: Cloning of a serotonin transporter affected by antidepressants. Science 1991; 254: 579-580
93. Schloss P, Williams DC: The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol 1998; 12:115-121
94. Owens MJ, Nemeroff CB: Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40:288-295
95. Morikawa O, Sakai N, Obara H, Saito N: Effects of interferon-α, interferon-γ and CAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349:317-324
96. Renault PF, Hoofnagle JH: Side effects of alpha interferon. Semin Liver Dis 1989; 9:273-277
97. Levenson JL, Fallon HJ: Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88: 760-761
98. Goldman LS: Successful treatment of interferon-alpha induced mood disorder with nortriptyline (letter). Psychosomatics 1994; 35:412-413
99. Valentine AD, Meyers CA, Talpaz M: Treatment of neurotoxic side effects of interferon-α with naltrexone. Cancer Invest 1995; 13:561-566
100. Byrne A, Byrne DG: The effect of exercise on depression, anxiety and other mood states: a review. J Psychosom Res 1993; 37:565-574
101. Francis J, Wright T, Jeffers L, Mitchell T, Howe E: Quality forum on hepatitis C virus. Veterans Health System J 1998; 3:96-102
102. Mohr DC, Goodkin DE, Likosky W, Gatto N, Banmann KA, Rudick RA: Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54:531-533
103. Von Ammon Cavanaugh S: Depression in the medically ill. Psychosomatics 1995; 36:48-59